TFF Group (TFFP)
Dec 13, 2024 - TFFP was delisted (reason: winding down operations)
0.0650
-0.0977 (-60.05%)
Inactive · Last trade price on Dec 12, 2024
TFF Pharmaceuticals Employees
TFF Group had 1,575 employees as of April 30, 2025. The number of employees decreased by 82 or -4.95% compared to the previous year.
Employees
1,575
Change (1Y)
-82
Growth (1Y)
-4.95%
Revenue / Employee
$306,460
Profits / Employee
$22,118
Market Cap
479.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 1,575 | -82 | -4.95% |
| Apr 30, 2024 | 1,657 | 292 | 21.39% |
| Apr 30, 2023 | 1,365 | 146 | 11.98% |
| Apr 30, 2022 | 1,219 | 18 | 1.50% |
| Apr 30, 2020 | 1,201 | -31 | -2.52% |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
TFFP News
- 9 months ago - TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration - PRNewsWire
- 1 year ago - TFF Pharmaceuticals Announces It Will Wind Down Operations - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing - GlobeNewsWire